NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis $1.77 +0.03 (+1.49%) As of 02:57 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Acrivon Therapeutics Stock (NASDAQ:ACRV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acrivon Therapeutics alerts:Sign Up Key Stats Today's Range$1.68▼$1.7950-Day Range$1.64▼$2.3952-Week Range$1.27▼$3.56Volume79,940 shsAverage Volume827,266 shsMarket Capitalization$75.68 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company Overview Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its proprietary OncoSignature platform to identify tumor characteristics that may predict a patient’s response to a particular therapy, with the goal of matching treatments to the patients most likely to benefit. Acrivon’s lead investigational product is ACR-368, an oral small-molecule therapy designed to target cell-cycle checkpoint mechanisms that cancer cells rely on for survival. The company is evaluating ACR-368 in biomarker-selected patient populations, including patients with ovarian and other solid tumors. Its pipeline also includes additional targeted oncology programs discovered through the OncoSignature platform. Founded in 2018, Acrivon is headquartered in Watertown, Massachusetts, and conducts research and clinical development activities primarily in the United States. The company is led by Peter Blume-Jensen, M.D., Ph.D., who serves as president and chief executive officer and has experience in oncology drug discovery and development.AI Generated. May Contain Errors. Read More Acrivon Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreACRV MarketRank™: 2.989354624085 of 5 starsAcrivon Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 293rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingAcrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAcrivon Therapeutics has a consensus price target of $13.50, representing about 667.5% upside from its current price of $1.76.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Acrivon Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Acrivon Therapeutics are expected to grow in the coming year, from ($1.76) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Acrivon Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.53% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 6.57.Change versus previous monthShort interest in Acrivon Therapeutics has recently increased by 7.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.56 News SentimentAcrivon Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Acrivon Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,370.00 in company stock.Percentage Held by Insiders10.50% of the stock of Acrivon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acrivon Therapeutics' insider trading history. Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRV Stock News HeadlinesAcrivon Therapeutics (NASDAQ:ACRV) Stock Price Down 0.6% - Here's What HappenedOctober 27 at 2:01 AM | americanbankingnews.comAcrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027October 20, 2026 | globenewswire.comElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he says is the same size Nvidia was a decade ago. The company holds 150 patents protecting its core technology, and Brown believes Elon Musk could soon drive major demand for it. A key catalyst is set for November 11.October 28 at 1:00 AM | Brownstone Research (Ad)Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare ConferenceSeptember 2, 2026 | globenewswire.comAcrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business OfficerAugust 31, 2026 | globenewswire.comAcrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data CatalystsAugust 13, 2026 | finance.yahoo.comAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 StudyAugust 5, 2026 | globenewswire.comAcrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 ConferenceJuly 21, 2026 | globenewswire.comSee More Headlines ACRV Stock Analysis - Frequently Asked Questions How have ACRV shares performed this year? Acrivon Therapeutics' stock was trading at $2.41 at the start of the year. Since then, ACRV stock has decreased by 27.0% and is now trading at $1.7590. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) issued its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.07. When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acrivon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Archer Aviation (ACHR), Biomea Fusion (BMEA), Cabaletta Bio (CABA) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings8/12/2026Today10/28/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 6 days, ACRV's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACRV CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees76Year FoundedN/APrice Target and Rating Average Price Target for Acrivon Therapeutics$13.50 High Price Target$19.00 Low Price Target$8.00 Potential Upside/Downside+662.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.14% Return on Assets-61.60% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book0.50Miscellaneous Outstanding Shares42,853,000Free Float38,353,000Market Cap$75.85 million OptionableNot Optionable Beta1.91 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ACRV) was last updated on 10/28/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
